NRx Pharmaceuticals (NRXP) Scheduled to Post Earnings on Thursday

NRx Pharmaceuticals (NASDAQ:NRXP) is scheduled to issue its quarterly earnings data after the market closes on Thursday, March 28th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

NRx Pharmaceuticals Trading Down 2.6 %

NRx Pharmaceuticals stock opened at $0.52 on Wednesday. NRx Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $1.20. The stock has a fifty day simple moving average of $0.46 and a two-hundred day simple moving average of $0.38. The firm has a market cap of $47.69 million, a price-to-earnings ratio of -1.01 and a beta of 0.99.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of NRXP. Vanguard Group Inc. grew its holdings in NRx Pharmaceuticals by 31.6% during the third quarter. Vanguard Group Inc. now owns 1,440,265 shares of the company’s stock valued at $1,065,000 after purchasing an additional 345,552 shares during the period. Millennium Management LLC bought a new position in shares of NRx Pharmaceuticals during the 2nd quarter valued at approximately $178,000. Royal Bank of Canada grew its stake in shares of NRx Pharmaceuticals by 135,799.2% during the 2nd quarter. Royal Bank of Canada now owns 171,233 shares of the company’s stock valued at $83,000 after acquiring an additional 171,107 shares during the period. Renaissance Technologies LLC purchased a new stake in NRx Pharmaceuticals in the 1st quarter worth approximately $341,000. Finally, State Street Corp raised its stake in NRx Pharmaceuticals by 1,009.1% during the 1st quarter. State Street Corp now owns 114,240 shares of the company’s stock worth $280,000 after acquiring an additional 103,940 shares during the period. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression.